Dermatology
Guideline | Onychomycosis
1 Jun, 2023 | 12:01h | UTCGuideline onychomycosis – Journal of the German Society of Dermatology
Consensus Paper | Safe skin, safe patients: the value of patient hygiene
31 May, 2023 | 14:06h | UTCSafe Skin, Safe Patients: The Value of Patient Hygiene – Clinical Consensus Statement – American Journal of Nursing (free for a limited period)
SR | Efficacy of negative pressure wound therapy in treating pressure ulcers remains uncertain
31 May, 2023 | 13:53h | UTCNegative pressure wound therapy for treating pressure ulcers – Cochrane Library
Summary: Negative pressure wound therapy for treating pressure ulcers – Cochrane Library
RCT | Microdosed incisional clindamycin reduces infection rate in skin cancer surgery
30 May, 2023 | 12:03h | UTCEffect of Microdoses of Incisional Antibiotics on the Rate of Surgical Site Infections in Skin Cancer Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
Commentary: Microdosed Incisional Clindamycin Cuts SSI After Skin Cancer Surgery – HealthDay
Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management
29 May, 2023 | 10:54h | UTC
MASCC Guidelines for the prevention and management of acute radiation dermatitis | Part 1 – Systematic review
29 May, 2023 | 10:53h | UTCRelated:
RCT | Bacterial decolonization for prevention of radiation dermatitis
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
Review | Skin assessments and interventions for maintaining skin integrity in nursing practice
25 May, 2023 | 11:25h | UTC
Guidelines on the diagnosis and treatment of foot infection in persons with diabetes
24 May, 2023 | 13:30h | UTC
RCT | Spironolactone enhances acne outcomes and offers a viable alternative to oral antibiotics
24 May, 2023 | 13:27h | UTCSummary: The SAFA (Spironolactone for Adult Female Acne) trial was a multicenter, phase 3, double-blind, randomized controlled trial in England and Wales and evaluated the efficacy of spironolactone for treating adult women with acne vulgaris. A total of 410 women, aged ≥18 years and suffering from facial acne for a minimum of six months, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo, increasing to 100 mg/day until week 24.
The primary outcome was measured by the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 and 24. The trial demonstrated that spironolactone improved Acne-QoL scores more effectively than the placebo, particularly at week 24. Additionally, more participants in the spironolactone group reported acne improvement, and treatment success was significantly higher in this group at week 12. Mild side effects, notably headaches, were more common in the spironolactone group.
The findings from the SAFA trial highlight spironolactone’s effectiveness, safety, and tolerability in treating adult women with acne vulgaris, suggesting it is a viable alternative to long-term antibiotic treatments. Future research is proposed on higher initial dosages of spironolactone, and its effects on different subgroups like patients with different ages, body mass index, and ethnicity.
Editorial: What do we know about prescribing spironolactone for acne? – The BMJ
News Release: Non-antibiotic treatment for women with persistent acne shown to be effective – University of Southhampton
Cohort Study | 5-mm margins may be adequate for T1a melanoma excision near critical structures
16 May, 2023 | 14:40h | UTCAssociation of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Melanoma Excisions with 5 Millimeter Margins Linked to Less Risk of Local Recurrence – HCP Live
Commentary on Twitter
Study on thin melanomas (T1a) near critical anatomic sites such as the head and face showed that 5-mm surgical margins may be safe for patients and decrease reconstructive surgery and potential adverse, including scarring and mental issues. https://t.co/Mw7Ub4xMVX
— JAMA Dermatology (@JAMADerm) April 12, 2023
The impact of hyperhidrosis on quality of life: a review of the literature
16 May, 2023 | 14:33h | UTC
Cutaneous Lupus Erythematosus | An update on pathogenesis and future therapeutic directions
12 May, 2023 | 13:28h | UTC
RCT | Bacterial decolonization for prevention of radiation dermatitis
8 May, 2023 | 12:46h | UTCBacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
News Release: A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy – Montefiore Einstein Cancer Center
Commentary on Twitter
Rand trial of 75 pts w/breast cancer + 2 with head/neck cancer showed no pts treated w/bacterial decolonization (BD) developed >gr 1 acute rad'n dermatitis (ARD), vs 24% of pts treated with standard of care, suggesting BD may be preventive vs ARD. https://t.co/6FAFH9kMt1 #RadOnc
— JAMA Oncology (@JAMAOnc) May 4, 2023
Cohort Study | Skin biopsy yields 88% sensitivity in detecting meningococcal Purpura Fulminans
5 May, 2023 | 15:15h | UTC
Review | A practical guide to hidradenitis suppurativa
4 May, 2023 | 13:29h | UTCA practical guide to hidradenitis suppurativa – Family Practice
Differential diagnosis, prevention, and treatment of mpox (Monkeypox): a review for dermatologists
3 May, 2023 | 15:27h | UTC
Supportive care management recommendations for mucocutaneous manifestations of monkeypox infection
3 May, 2023 | 15:26h | UTC
Review | Calciphylaxis and kidney disease
3 May, 2023 | 15:20h | UTCCalciphylaxis and Kidney Disease: A Review – American Journal of Kidney Diseases
RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis
3 May, 2023 | 15:04h | UTCCommentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live
Commentary on Twitter
The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE
— JAMA Dermatology (@JAMADerm) April 19, 2023
Syphilis in dermatology | Recognition and management
2 May, 2023 | 13:40h | UTCSyphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology
Commentary on Twitter
Syphilis in Dermatology: Recognition and Management
This guide by Amor Khachemoune et al. discusses the current epidemiology of syphilis and focuses on practice aspects of diagnosis and management, including public health reporting.#Syphilishttps://t.co/uLsVaw4jXP pic.twitter.com/sbXhFCk5De— Kathy Fraser (@AmJClinDerma) January 23, 2023
USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations
24 Apr, 2023 | 14:07h | UTCScreening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Patient Page: Screening and Prevention of Skin Cancer – JAMA
Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA
Commentary on Twitter
2023 Recommendation Statement from the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for #skincancer in adolescents and adults (I statement). https://t.co/WB6VN2r1Nv
— JAMA (@JAMA_current) April 18, 2023
RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata
21 Apr, 2023 | 13:00h | UTCEfficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Progress in search for alopecia areata treatment for adolescents – Yale News
Commentary on Twitter
Ritlecitinib might be a treatment option for alopecia areata in patients aged 12 years and older, suggests a new study: https://t.co/jKUxEbo4AZ
Below, a graphical abstract 👇 pic.twitter.com/JIJtTGHeE4
— The Lancet (@TheLancet) April 17, 2023
Podcast | Fungi fun! an in-depth look at tinea infections in children
18 Apr, 2023 | 13:14h | UTCFungi Fun! An In-Depth Look at Tinea Infections – The Cribsiders
Phase 2 RCT | Dersimelagon in erythropoietic protoporphyrias
17 Apr, 2023 | 13:05h | UTCDersimelagon in Erythropoietic Protoporphyrias – News England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, once-daily oral treatment with dersimelagon safely improved tolerance to sun exposure in patients with erythropoietic protoporphyria and X-linked protoporphyria. https://t.co/peZye8R5T7 pic.twitter.com/DO2HmKkM1f
— NEJM (@NEJM) April 12, 2023
RCTs | Eczema Care Online behavioral interventions may support self-care for children and young people
12 Apr, 2023 | 13:02h | UTCEditorial: How to make Eczema Care Online freely available – The BMJ
News Release: New website helps improve eczema in children and young people – University of Southampton